Works matching IS 13524585 AND DT 2022 AND VI 28 AND IP 10
Results: 21
The value of patient-reported outcome measures for multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1489, doi. 10.1177/13524585221111675
- By:
- Publication type:
- Article
It is imperative to reconsider the concept of seronegative NMOSD.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1654, doi. 10.1177/13524585221111057
- By:
- Publication type:
- Article
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1606, doi. 10.1177/13524585221105465
- By:
- Publication type:
- Article
A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1651, doi. 10.1177/13524585221097564
- By:
- Publication type:
- Article
All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: Commentary.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1502, doi. 10.1177/13524585221097562
- By:
- Publication type:
- Article
All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: Yes.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1498, doi. 10.1177/13524585221092636
- By:
- Publication type:
- Article
All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: No.
- Published in:
- 2022
- By:
- Publication type:
- Product Review
Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1641, doi. 10.1177/13524585221083982
- By:
- Publication type:
- Article
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1576, doi. 10.1177/13524585221079731
- By:
- Publication type:
- Article
Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1553, doi. 10.1177/13524585221081090
- By:
- Publication type:
- Article
The expansion and severity of chronic MS lesions follows a periventricular gradient.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1504, doi. 10.1177/13524585221080667
- By:
- Publication type:
- Article
Association of pregnancies with risk of multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1630, doi. 10.1177/13524585221080542
- By:
- Publication type:
- Article
Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1541, doi. 10.1177/13524585221079744
- By:
- Publication type:
- Article
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1591, doi. 10.1177/13524585221083194
- By:
- Publication type:
- Article
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1620, doi. 10.1177/13524585221079200
- By:
- Publication type:
- Article
Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1658, doi. 10.1177/13524585221079044
- By:
- Publication type:
- Article
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1562, doi. 10.1177/13524585221078825
- By:
- Publication type:
- Article
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1526, doi. 10.1177/13524585221076717
- By:
- Publication type:
- Article
No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1656, doi. 10.1177/13524585221075744
- By:
- Publication type:
- Article
Serum neurofilament light in MS: The first true blood-based biomarker?
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1491, doi. 10.1177/1352458521993066
- By:
- Publication type:
- Article
Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1515, doi. 10.1177/13524585211073761
- By:
- Publication type:
- Article